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Background: Obesity is becoming more prevalent and thus growing as a public health concern in patients with
schizophrenia. This investigation evaluated the relationship between body weight and the self-reported quality of
life (QOL) of Japanese patients with schizophrenia.
Methods: We recruited outpatients (n=225) aged 42.5 ± 12.8 (mean ± SD) years with a DSM-IV diagnosis of
schizophrenia who were admitted to psychiatric hospitals. This study used a cross-sectional design. The assessments
included an interview to obtain sociodemographic data, the second version of the Short Form Health Survey
(SF-36v2), the 10-item version of the Drug Attitude Inventory (DAI-10), the Clinical Global Impression-Severity (CGI-S)
and height and weight measurements. SF-36v2 subscores were examined for differences based on the following
body mass index (BMI) categories: healthy weight (BMI < 24.9), overweight (BMI 25–29.9) and obese (BMI > 30).
A multiple regression analysis was employed to assess the relationship between these BMI categories and QOL
outcomes.
Results: The overall prevalence of obesity in our sample was 16.4%. A multiple regression model revealed that age,
gender, DAI-10 scores, CGI-S scores, social functioning, role emotional functioning, mental health, and Mental
Composite Summary (MCS) score were significantly and positively associated with overweight status. Physical
functioning, general health, role emotional functioning, mental health, and a physical composite summary (PCS)
score were significantly and negatively associated with obesity.
Conclusions: The burden of obesity is both a physical and a mental problem. An obesity intervention program for
patients with schizophrenia may improve health-related QOL in patients with schizophrenia.
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Obesity is a growing public health concern, as is becom-
ing more prevalent among patients with schizophrenia
compared with the general population [1-3]. Previous
studies have shown that being overweight is a major risk
factor for metabolic syndrome, cardiovascular diseases,
and premature death. Furthermore, this risk is nearly
twice that of the general population among patients with
schizophrenia [4-6]. In addition, obesity among patients
with schizophrenia is associated with high medication
costs [7], low self-esteem, poor psychosocial adaptation* Correspondence: nsuga3@yahoo.co.jp
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reproduction in any medium, provided the or[8], non-compliance with an antipsychotic medication
regime [9] and reduced quality of life (QOL) [10].
QOL can be defined as the impact of illness and con-
dition on the physical and mental functioning from the
point of view of the patient. Patients with schizophrenia
have low QOL [11]. Previous studies of Western popu-
lations have shown that the QOL of patients with
schizophrenia further decreased with obesity [10,12-14].
However, we are not aware any study concerning this
issue among Asian populations, who have a different
obesity prevalence and lifestyle from Western popula-
tions [15-17]. QOL can be used to assess how patients
feel and function in their everyday life with regard to a
treatment, and a good QOL may improve the measure-
ment of treatment efficacy. Directly treating QOLral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ate symptoms of the disorder [18,19]; thus, understand-
ing the association between obesity and QOL would be
useful.
This investigation evaluated the relationship between
body weight and the self-reported QOL of Japanese pa-
tients with schizophrenia. To our knowledge, this study




This study was conducted between June 2011 and
August 2011. The participants included 225 outpatients
(106 males and 119 females) from four psychiatric hospi-
tals in Japan who were diagnosed with either schizo-
phrenia or schizoaffective disorder according to the
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV) diagnostic criteria. Patients’
diagnoses established by experienced psychiatrists re-
sponsible for their treatment were recorded from their
medical charts. The Ethics Committee of the Hirosaki
University School of Medicine approved the data collec-
tion for this study, and all participants provided written
informed consent before volunteering.
Procedure
Participant demographic data (age and sex) were
obtained from their medical records. Participant height
and weight were measured, and body mass index (BMI)
was calculated for each participant. Participants were
classified as having a normal weight if their BMI was
below 25, overweight if their BMI was between 25 and
29.9, and obese if their BMI was 30 or above. The Clin-
ical Global Impression-Severity (CGI-S) score was used
to measure symptom severity. The CGI-S asks the clin-
ician one question: “Considering your total clinical ex-
perience with this particular population, how mentally ill
is the patient at this time?” This question is rated from 1
(normal, not at all ill) to 7 (among the most extremely ill
patients). The Drug Attitude Inventory (DAI) is a self-
applied scale that measures subjective responses to
medication. This instrument reveals whether the patient
is satisfied with their treatment and evaluates their un-
derstanding of how the treatment is affecting them. The
reduced version of the DAI (DAI-10) has ten highly
specific items concerning the participant’s subjective ex-
perience. These items are based on the recorded and
transcribed accounts of the patients, and the response
options are true or false. These items were selected for
their ability to discriminate between grades of medica-
tion adherence in a way that could be analyzed.
The Short Form Health Survey, Version 2 (SF-36v2)
was used to assess participants’ health-related QOL. TheSF-36v2 is a standardized, 36-item, self-administered
questionnaire that was translated, adapted, and validated
for use in Japan [20,21]. This questionnaire assesses
eight QOL domains of health status. The domains
concerning physical health consist of physical function-
ing, role physical functioning, body pain, and general
health. The domains concerning mental health consist of
vitality, social functioning, role emotional functioning,
and mental health. For each QOL domain, a score ran-
ging from 0 to 100 is calculated, and higher scores indi-
cate more positive perceptions of health-related QOL. In
addition, the scores from all eight domains are combined
to create more comprehensive indicators of physical and
mental health: the Physical Composite Summary (PCS)
and the Mental Composite Summary (MCS). The PCS
and MCS are standardized (Japanese mean = 50, stand-
ard deviation = 10) to compare with the general popula-
tion or the results of other studies.
Statistical analyses
Descriptive analyses were performed on the demo-
graphic and clinical variables. An analysis of variance
(ANOVA) and the Tukey post-hoc test were performed
to compare the primary continuous demographic and
clinical characteristics between groups, and a chi-square
test was performed to analyze categorical variables. Data
are presented as the mean ± SD. A multiple linear re-
gression was employed to analyze the effects of obesity
on the SF-36v2 continuous variables. Regression analyses
were conducted to adjust for confounding factors (age,
gender, DAI-10, and CGI-S). A value of p<0.05 was con-
sidered significant. The data were analyzed using PASW
Statistics software for Windows, version 18.0.0.
Results
Demographic characteristics
Table 1 presents the participants’ characteristics. The
obese group, but not the overweight group, showed
lower physical functioning score compared with the
healthy weight group. General health and role emotional
functioning scores were higher for the overweight group
compared with the obese group. The overweight group,
but not the obese group, had higher MCS scores com-
pared with the healthy weight group. No differences
were observed with regard to the other characteristics.
Factors that influenced the SF-36
Table 2 shows the multiple regression results for the
SF-36 scores. The physical functioning, role emotional
functioning, and mental health domains and the PCS
and MCS scores were significantly associated with age.
Role physical functioning and PCS score were signifi-
cantly and positively associated with gender (being
male). All eight domains of the SF-36 and the PCS and
Table 1 Characteristics by BMI group
Body mass index
Total Healthy weight Overweight Obesity ANOVA
BMI<25 25≦BMI<30 BMI≧30 p value
n 225 123 65 37
Age 42.5±12.8 42.0±13.6 44.6±11.4 40.4±12.2 0.234
Gender
Male 106 Male 54 Male 36 Male 16
0.284
Female 119 Female 69 Female 29 Female 21
Height 163.7±8.9 163.3±8.8 165.0±9.1 162.9±9.4 0.383
Weight 68.0±15.7 58.2±9.2 73.9±9.3 90.5±13.5 <0.001 a
Clinical Global Impression Severity scale 3.1±1.0 3.1±1.0 3.2±1.0 3.2±0.9 0.521
Drug Attitude Inventory-10 6.9±2.3 6.9±2.2 6.7±2.3 7.3±2.4 0.496
Short Form Health Survey Version 2
Physical functioning 44.3±12.9 46.1±11.0 44.1±13.8 38.7±15.8 <0.01 b
Role physical functioning 42.0±13.5 42.5±13.9 42.6±12.2 39.4±14.4 0.431
Body pain 49.2±11.1 48.6±10.8 50.8±11.5 48.5±11.5 0.384
General health 45.6±10.5 45.5±10.0 47.6±10.2 42.0±11.7 <0.05 c
Vitality 45.2±11.4 44.7±11.8 47.3±11.1 43.0±10.6 0.155
Social functioning 42.0±13.4 40.8±14.0 44.9±11.6 40.6±14.2 0.112
Role emotional functioning 40.2±14.2 39.5±14.3 43.8±12.0 36.4±16.4 <0.05 c
Mental health 43.7±11.3 43.0±11.1 46.3±11.2 41.3±11.3 0.057
Physical composite score 42.2±13.0 43.1±12.5 43.0±12.1 38.1±15.6 0.108
Mental composite score 46.0±11.0 44.8±11.0 48.9±10.7 44.7±10.4 <0.05 d
Data are presented as the means ± SD.
a Indicates a significant difference (P < 0.05) between the healthy weight group versus the overweight group, the healthy weight group versus the obesity group
and the overweight group versus the obesity group.
b Indicates a significant difference (P < 0.05) between the healthy weight group and the obesity group.
c Indicates a significant difference (P < 0.05) between the overweight group and the obesity group.
d Indicates a significant difference (P < 0.05) between the healthy weight group and the overweight group.
ANOVA = analysis of variance.
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scores. Role physical functioning, body pain, general
health, vitality, social functioning, mental health, and the
MCS score were significantly associated with the DAI-10
scores. Social functioning, role emotional functioning,
mental health, and the MCS score were significantly and
positively associated with an overweight status. Physical
functioning, general health, role emotional functioning,
mental health, and PCS score were significantly and
negatively associated with obesity.Discussion
The present study is the first to examine the association
between obesity and the QOL of patients diagnosed with
schizophrenia in an Asian population. In this sample,
16.4% of participants with schizophrenia were obese.
After adjusting for confounds, three domains of mental
health and the MCS score were significantly and posi-
tively associated with an overweight status. In addition,
obesity was significantly and negatively associated withtwo domains of physical health, two domains of mental
health, and the PCS score in the same model.
Previous studies have found a relationship between
obesity and QOL among patients with schizophrenia in
Western populations [10,12,14,22]. Allison and col-
leagues investigated the relationship between QOL and
weight gain among 286 patients with schizophrenia.
After adjusting for confounds, they found that weight
gain was significantly associated with a poorer overall
QOL score according to a 16-item scale. Another study
from the US used the SF-36 and found an association
between obesity and some QOL items among 143 pa-
tients with schizophrenia. Worse physical functioning,
general health, role emotional functioning, and a lower
PCS score were observed among obese participants.
Faulkner and colleagues reported that a PCS score of
SF-12 was associated with BMI and waist circumference
among 90 patients with schizophrenia. Furthermore,
Kolotkin and colleagues studied 111 patients with
schizophrenia and 100 patients with bipolar disorder
and found that obese patients had poorer vitality, social
Table 2 Factors that influenced the Short Form 36 (SF-36) scores
Multiple regression statistics
Independent variables B SE β t value p value
Physical functioning Age −0.493 0.087 −0.352 −5.681 <0.001
Gender (being male) 4.019 2.180 0.112 1.844 0.067
CGI-S −3.931 1.100 −0.218 −3.574 <0.001
DAI-10 0.631 0.486 0.080 1.298 0.196
Overweight −1.275 2.513 −0.035 −0.507 0.612
Obesity −9.400 3.379 −0.195 −2.782 <0.01
Role physical functioning Age −0.138 0.129 −0.070 −1.073 0.285
Gender (being male) 7.725 3.235 0.152 2.388 <0.05
CGI-S −7.770 1.632 −0.304 −4.760 <0.001
DAI-10 1.799 0.721 0.162 2.495 <0.05
Overweight 1.299 3.729 0.025 0.348 0.728
Obesity −6.875 5.014 −0.100 −1.371 0.172
Body pain Age −0.154 0.127 −0.079 −1.206 0.229
Gender (being male) 4.775 3.198 0.096 1.493 0.137
CGI-S −7.642 1.614 −0.304 −4.735 <0.001
DAI-10 1.743 0.713 0.160 2.446 <0.05
Overweight 6.441 3.687 0.129 1.747 0.082
Obesity −6.340 4.957 −0.094 −1.279 0.202
General health Age 0.010 0.099 0.007 0.101 0.919
Gender (being male) 1.648 2.486 0.042 0.663 0.508
CGI-S −5.579 1.2544 −0.282 −4.447 <0.001
DAI-10 1.885 0.554 0.219 3.403 <0.01
Overweight 4.915 2.866 0.125 1.715 0.088
Obesity −11.389 3.854 −0.215 −2.955 <0.01
Vitality Age 0.134 0.115 0.077 1.167 0.245
Gender (being male) 2.645 2.892 0.059 0.915 0.361
CGI-S −4.662 1.459 −0.208 −3.195 <0.01
DAI-10 1.684 0.644 0.173 2.614 <0.05
Overweight 5.348 3.333 0.120 1.604 0.110
Obesity −8.476 4.482 −0.141 −1.891 0.060
Social functioning Age 0.239 0.131 0.117 1.822 0.070
Gender (being male) 1.076 3.298 0.021 0.326 0.745
CGI-S −7.187 1.664 −0.274 −4.319 <0.001
DAI-10 2.213 0.735 0.194 3.012 <0.01
Overweight 8.733 3.801 0.167 2.297 <0.05
Obesity −8.503 5.111 −0.121 −1.664 0.098
Role emotional Age 0.327 0.143 0.147 2.294 <0.01
functioning Gender (being male) 6.848 3.585 0.120 1.910 0.057
CGI-S −8.015 1.809 −0.280 −4.431 <0.001
DAI-10 1.192 0.799 0.096 1.492 0.137
Overweight 8.428 4.132 0.148 2.040 <0.05
Obesity −13.373 5.556 −0.174 −2.407 <0.05
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Table 2 Factors that influenced the Short Form 36 (SF-36) scores (Continued)
Mental health Age 0.277 0.105 0.169 2.647 <0.01
Gender (being male) 2.443 2.631 0.058 0.929 0.354
CGI-S −4.804 1.327 −0.228 −3.620 <0.001
DAI-10 1.912 0.586 0.209 3.262 <0.01
Overweight 6.380 3.032 0.152 2.104 <0.05
Obesity −9.008 4.077 −0.160 −2.209 <0.05
Physical composite score Age −0.186 0.065 −0.182 −2.873 <0.01
Gender (being male) 4.153 1.623 0.159 2.558 <0.05
CGI-S −4.200 0.819 −0.320 −5.127 <0.001
DAI-10 0.624 0.362 0.110 1.726 0.086
Overweight 0.660 1.871 0.025 0.353 0.725
Obesity −5.544 2.516 −0.158 −2.204 <0.05
Mental composite score Age 0.183 0.054 0.213 3.364 <0.01
Gender (being male) 0.035 1.364 0.002 0.026 0.979
CGI-S −2.211 0.688 −0.200 −3.212 <0.01
DAI-10 1.024 0.304 0.214 3.369 <0.01
Overweight 4.163 1.572 0.189 2.648 <0.01
Obesity −4.067 2.114 −0.138 −1.924 0.056
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health and lower MCS scores than those patients who
were not obese. The contradictory results concerning
the overweight group in our study may be due to cul-
tural or ethnic differences. Asian participants who were
overweight may have fewer negative attitudes regarding
their weight than Western participants of a similar
weight [23,24]. Another explanation is that the preva-
lence of obesity in our study was lower than that of the
studies of Western populations. In addition, some stud-
ies have compared each QOL domain among patients
with schizophrenia using a mixed subject pool of pa-
tients who were either overweight or obese.
Our findings have implications for clinicians who treat
patients with schizophrenia. First, obesity adds to the
burden of schizophrenia not only via physical health
risks but also reduced health-related QOL. The cause of
obesity among patients with schizophrenia has not been
determined completely. However, patients with schizo-
phrenia are at risk for developing obesity due to poor
dietary habits, lower resting energy expenditures, a lack
of exercise, and limited activity due to their negative
symptoms [25,26]. Previous studies have shown that
non-pharmacological interventions can reduce body
weight [22,27]. Effective treatments are necessary, and
these range from nutritional interventions to cognitive
behavioral therapy. Second, a pervasive impairment in
QOL among patients with schizophrenia may cause poor
adherence or even premature discontinuation of treat-
ment because of weight gain. A previous study ofpatients with schizophrenia showed that both BMI
and subjective distress from weight gain predicted non-
compliance with medications even after adjusting for
other possible confounds [9]. Obese patients are also
more than twice as likely as those patients with normal
BMIs to report noncompliance with medication.
The present study is limited by its cross-sectional
design; thus, we cannot determine a causal relationship
between obesity and QOL among patients with schizo-
phrenia. A follow-up survey must be conducted. The
second limitation of this study was the patient recruit-
ment, which was restricted to outpatients admitted to
the hospital for a review of their health problems. These
individuals may not represent all patients with schizo-
phrenia (e.g., children, adolescents, or non-medicated
patients). Third, not all possible parameters were in-
cluded in this study, such as socio-economic status, diet-
ary habits, physical activity levels, the duration of illness
and treatment, schizophrenic symptoms and medica-
tions. Above mentioned parameters are known to be in-
dependently associated with health related QOL or
lifestyle, also in patients with schizophrenia [28,29]. In
particular, the presence of antipsychotic medications
may be an important factor. The use of first- versus
second-generation antipsychotics may also affect the re-
sults. A stratified analysis by medication is needed in a
future study. Fourth, data on validity of the SF-36v2
were lacking in Japanese patients with schizophrenia. In-
terpretation of our results was hampered by lacking data
of the validation study for SF-36 v2.
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Obesity has a significant and negative impact on the
QOL of patients with schizophrenia regardless of symp-
tom severity and their attitudes toward antipsychotics.
Previous studies suggest that long-term programs that
incorporate nutrition, exercise, and behavioral interven-
tions can prevent weight gain among patients with
schizophrenia. An intervention program aimed at redu-
cing obesity has the potential to improve patient health-
related QOL among patients with schizophrenia.
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